BioTelemetry, Inc. (NASDAQ:BEAT) shares traded down 5.3% on Monday . The company traded as low as $29.60 and last traded at $29.75. 717,401 shares traded hands during trading, an increase of 58% from the average session volume of 453,740 shares. The stock had previously closed at $31.40.

A number of research analysts recently weighed in on the stock. Raymond James Financial assumed coverage on shares of BioTelemetry in a research report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target on the stock. BidaskClub raised shares of BioTelemetry from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Dougherty & Co reissued a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. SunTrust Banks assumed coverage on shares of BioTelemetry in a research report on Monday, October 23rd. They set a “buy” rating and a $41.00 price target on the stock. Finally, Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $42.86.

The firm has a market cap of $964.14, a PE ratio of 22.63, a P/E/G ratio of 1.40 and a beta of 0.53. The company has a quick ratio of 1.48, a current ratio of 1.60 and a debt-to-equity ratio of 0.75.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.09). The company had revenue of $81.02 million during the quarter, compared to the consensus estimate of $82.10 million. BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The business’s revenue was up 52.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 EPS. analysts forecast that BioTelemetry, Inc. will post 0.83 EPS for the current year.

A number of hedge funds have recently made changes to their positions in BEAT. Rhumbline Advisers increased its stake in shares of BioTelemetry by 2.2% in the second quarter. Rhumbline Advisers now owns 54,088 shares of the medical research company’s stock worth $1,809,000 after purchasing an additional 1,158 shares in the last quarter. Legal & General Group Plc increased its stake in shares of BioTelemetry by 10.9% in the second quarter. Legal & General Group Plc now owns 52,118 shares of the medical research company’s stock worth $1,741,000 after purchasing an additional 5,139 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of BioTelemetry by 43.3% in the second quarter. BNP Paribas Arbitrage SA now owns 8,401 shares of the medical research company’s stock worth $281,000 after purchasing an additional 2,540 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of BioTelemetry by 17.6% in the second quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after purchasing an additional 626 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of BioTelemetry in the second quarter worth about $347,000. 82.34% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “BioTelemetry (BEAT) Shares Down 5.3%” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/biotelemetry-beat-shares-down-5-3/1801311.html.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.